Quarter of all cancers found at late stage
November 15, 2010Cancer, England, NCIN, NHS, National Cancer Intelligence Network, brain cancer, cancer diagnosis, leukaemia
Nearly a quarter of all cancer diagnoses in England came after a patient had been admitted to hospital for emergency …
Irish cost-effectiveness guidelines published
November 15, 2010Sales and Marketing Dr Mairin Ryan, Economic Evaluation of Health Technologies, HIQA, Health Information and Quality Authority, IPHA, Ireland, Irish Pharmaceutical Healthcare Association, NICE, hta
The Irish government has published new health technology assessment guidelines to help decision-makers estimate the cost-effectiveness of medical treatments. The …
AstraZeneca staff strike as pension talks breakdown
November 15, 2010Manufacturing and Production AZ, AstraZeneca, AstraZeneca UK Manufacturing, GMB, Hurdsfield Industrial Estate, pensions, strikes, unions
Workers at an AstraZeneca facility in the UK went back on strike for the eighth time last week after talks …
Tylenol recall warrants thorough, public investigation, says ISMP
November 15, 2010Manufacturing and Production FDA, ISMP, Institute for Safe Medication Practices, Johnson & Jonson, MedWatch, Tylenol, Tylenol recall
Johnson & Jonson’s recall of Tylenol painkiller products was one of the key safety trends identified in the last quarter …
Sam Barnes joins Axon Communications
November 12, 2010Medical Communications AXON Communications, Joss Lyons-White, Sam Barnes, appointment, medical communications
Surrey, UK-based agency Axon Communications has appointed Sam Barnes director of PR. Sam has over 15 years of experience in healthcare …
Digital Pharma: Pfizer and Boehringer’s online COPD awareness
November 12, 2010Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease
Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …
Bavarian Nordic courting cancer vaccine backers
November 12, 2010Research and Development, Sales and Marketing Bavarian Nordic, Dendreon, Prostvac, Provenge, TroVax, cancer vaccine, prostate cancer, prostate cancer vaccine, zibotentan
Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …
FDA approves Merck’s HIV fat drug Egrifta
November 12, 2010Research and Development, Sales and Marketing EMD Serono, Egrifta, FDA, HIV, Merck KGaA, abdominal fat in HIV, tesamorelin
US regulatory authorities have approved the first treatment indicated to target abdominal fat in patients with HIV after trials showed …
Germany to cut drug prices by 2 billion euro
November 12, 2010Sales and Marketing Cornelia Yzer, GKV-Spitzenverband, Germany, IQWIG, Philipp Rosler, VFA, health insurers, healthcare spending, innovative medicines
The lower house of the German Parliament has passed a new law to control the cost of new prescription medicines. …
NICE stands firm on Avastin rejection
November 12, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme
NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …
ABPI appoints communications director
November 11, 2010Research and Development, Sales and Marketing ABPI, Amanda Callaghan, Royal College of Nursing, appointment, research and development, sales and marketing
UK industry body the ABPI has appointed Amanda Callaghan director of corporate communications. She starts the role on 31 January …
UCB lupus candidate shows disease benefits
November 11, 2010Benlysta, Lupus, UCB, epratuzumab, monoclonal antibody, systemic lupus erythematosus
A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer …
Nycomed’s Q3 undermined by pantoprazole decline
November 11, 2010Sales and Marketing Daxas, Guangdong Techpool Bio-Pharma, Nycomed, Protium, pantoprazole
Nycomed has seen its sales inch downwards in the third quarter, as the decline of its biggest seller pantoprazole continued. …
Pfizer enters drug repositioning collaboration with Biovista
November 11, 2010Research and Development Biovista, FDA, Neurontin, Pfizer, Pfizer Indications Discovery Unit, drug repositioning, viagra
Pfizer has signed a pilot research agreement with drug repositioning specialist Biovista. The aim of the collaboration is to identify …
Patients in UK cancer trials quadruples
November 11, 2010Research and Development Cancer Research UK, NCRI, National Cancer Research Institute, UK clinical research, cancer trials
The number of cancer patients in the UK participating in clinical studies has quadrupled in the last decade, according to …
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Digital for digital’s sake is out
November 10, 2010Medical Communications digital creativity, digital marketing, ipad, seven stones, youtube
Creativity in the digital world is twofold. On the one hand there is technical wizardry and, on the other, there …
RSA expands global team
November 10, 2010Business Services Matthew Edwards, Michelle Bosshard, Yildiz Biloglu, Zaki Sellam, appointment, business services, rsa
Life sciences executive search and interim management company RSA has made a number of appointments and internal promotions across its …
Sanofi’s C diff vaccine fast tracked by FDA
November 10, 2010Research and Development C diff, C diff vaccine, C difficile, Clostridium difficile, FDA, FDA fast-track, Sanofi, Sanofi Pasteur
A new vaccine aimed at preventing C difficile infections has been fast tracked by the FDA. The regulator’s decision signals …
Genzyme again snubs suitor Sanofi
November 10, 2010Research and Development, Sales and Marketing Campath, Chris Viehbacher, Genzyme, Henri Termeer, Orphan Drugs, Plavix, Sanofi, Sanofi-Aventis, manufacturing compliance
Genzyme has once again snubbed Sanofi-Aventis as the French pharma firm continues its pursuit of the beleaguered biotech company. Henri …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
